285 lines
48 KiB
Text
285 lines
48 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK548135">
|
|
<meta name="ncbi_domain" content="livertox">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK548135/?report=reader">
|
|
<meta name="ncbi_pagename" content="Nintedanib - LiverTox - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Nintedanib - LiverTox - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/livertox/Nimodipine/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/livertox/Niraparib/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/livertox/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]">
|
|
<meta name="citation_title" content="Nintedanib">
|
|
<meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="citation_date" content="2023/12/12">
|
|
<meta name="citation_pmid" content="31643465">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548135/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Nintedanib">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="DC.Date" content="2023/12/12">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548135/">
|
|
<meta name="description" content="Nintedanib is an orally available tyrosine kinase receptor antagonist that inhibits collagen formation and is used to treat idiopathic pulmonary fibrosis. Elevations in serum enzyme levels during nintedanib therapy are not uncommon and multiple instances of acute liver injury with symptoms and jaundice have been reported since its approval and more widescale use.">
|
|
<meta name="og:title" content="Nintedanib">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Nintedanib is an orally available tyrosine kinase receptor antagonist that inhibits collagen formation and is used to treat idiopathic pulmonary fibrosis. Elevations in serum enzyme levels during nintedanib therapy are not uncommon and multiple instances of acute liver injury with symptoms and jaundice have been reported since its approval and more widescale use.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548135/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/livertox/Nintedanib/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548135/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8D77AF7D7E1A5100000000008A0073.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK548135/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/livertox/Nimodipine/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Nintedanib</div><div class="j">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</div></div><div class="tail"><a href="/books/n/livertox/Niraparib/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK548135/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK548135/&text=Nintedanib"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/livertox/?report=reader">Title Information</a><a href="/books/n/livertox/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK548135/?report=classic">Switch to classic view</a><a href="/books/NBK548135/pdf/Bookshelf_NBK548135.pdf">PDF (110K)</a><a href="/books/NBK548135/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK548135%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8D77AF7D7E1A5100000000008A0073.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK548135_"><span class="title" itemprop="name">Nintedanib</span></h1><p class="fm-aai"><a href="#_NBK548135_pubdet_">Publication Details</a></p></div></div><div class="body-content whole_rhythm" itemprop="text"><div id="Nintedanib.OVERVIEW"><h2 id="_Nintedanib_OVERVIEW_">OVERVIEW</h2><div id="Nintedanib.Introduction"><h3>Introduction</h3><p>Nintedanib is an orally available tyrosine kinase receptor antagonist that inhibits collagen formation and is used to treat idiopathic pulmonary fibrosis. Elevations in serum enzyme levels during nintedanib therapy are not uncommon and multiple instances of acute liver injury with symptoms and jaundice have been reported since its approval and more widescale use.</p></div><div id="Nintedanib.Background"><h3>Background</h3><p>Nintedanib (nin ted' a nib) is a small molecular weight tyrosine kinase receptor inhibitor that has potent activity against several growth factor receptors, including vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), and platelet derived growth factor receptor (PDGFR). The inhibition of these receptors causes modulation of many intracellular pathways including inhibition of activities of pro-fibrotic mediators such as transforming growth factor-beta (TGF-β), and decrease in synthesis of extracellular matrix proteins including collagen and fibronectin. Nintedanib has been evaluated as therapy for many different forms of fibrotic lung diseases as well as several forms of cancer. In several large clinical trials, therapy with nintedanib was associated with a decrease in the progressive decline in lung function in patients with idiopathic pulmonary fibrosis, as well as with a decrease in symptomatic, acute pulmonary exacerbations. On the basis of these studies, nintedanib was approved for use in idiopathic pulmonary fibrosis in the United States in 2014 and subsequently for other chronic fibrotic lung diseases such as systemic sclerosis associated lung disease and other chronic fibrosing interstitial lung diseases. However, it has not been approved for use in cancer. Nintedanib is available as capsules of 100 and 150 mg generically and under the brand name OFEV. The typical initial dose in adults is 150 mg orally twice daily. Temporary or permanent dose reduction is advised for management of adverse reactions or poor tolerability. Side effects are common and include diarrhea, nausea, dyspepsia, abdominal pain, decreased appetite, headache and fatigue. Rare, but potentially severe adverse events include excessive bleeding, poor wound healing, gastrointestinal perforation, liver injury, embryo-fetal toxicity, and arterial thrombotic events.</p></div><div id="Nintedanib.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In large preregistration randomized controlled trials, serum enzyme elevations occurred in 8% to 16% of patients receiving nintedanib compared to 3% of controls. Aminotransferase values above 3 times the upper limit of normal (ULN) occurred in only 3% to 5% of patients (compared to <1% of controls), and discontinuation of therapy because of ALT elevations was required in less than 1% of nintedanib treated subjects. The enzyme elevations during nintedanib therapy were generally not accompanied by symptoms of liver injury or jaundice and resolved even without dose modification in many subjects. Subsequent to the approval of nintedanib as therapy for fibrotic pulmonary diseases, several reports of clinically apparent liver injury attributable to its use were published from Asia, Europe, and the United States. In reported cases, the latency to onset ranged for 4 to 24 months and the pattern of enzyme elevations ranged from cholestatic to hepatocellular. Fatal cases have been reported to the sponsor and to the FDA, but details of the liver injury were not well defined and the causality was often only possible or at most probable. Analysis of rates of ALT and AST elevations during nintedanib therapy have been reported to be as high as 68%, but usually self-limited and not accompanied by jaundice. Injury appears to be more frequent in the elderly, in Asians, and in patients with lower body weight and body surface area. Starting treatment at 100 mg twice daily and dose reduction to 100 mg twice daily appears to be associated with lower rates of aminotransferase elevations.</p><p>These reports, however, led to revisions of the product label that now include warnings of liver injury that could be severe and even fatal. Warnings were also added to use caution in treating patients with concurrent known liver disease. Monitoring of liver tests are recommended by expert panels at baseline and at least monthly for the first 3 months and every 3 months thereafter. Thus, nintedanib is likely to cause clinically apparent liver injury, and careful monitoring and early discontinuation (as was done in the preregistration studies) may prevent its occurrence.</p><p>Likelihood score: C (probable cause of clinically apparent liver injury that can be severe and even fatal).</p></div><div id="Nintedanib.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The mechanism by which nintedanib might cause liver injury is not known. It is metabolized in the liver largely via the cytochrome P450 system and idiosyncratic liver injury may be due to its metabolism to a toxic or immunogenic intermediate. Comparison of clinical features of patients with and without hepatic injury during nintedanib therapy suggests that hepatic enzyme elevations are more frequent in patients with a low body weight and body surface area suggesting that pharmacokinetic features may underlie risk for injury, which would explain the higher rates in the elderly and in Asians. Nintedanib is also susceptible to drug-drug interactions with strong inducers or inhibitors of CYP 3A4.</p></div><div id="Nintedanib.Outcome_and_Management"><h3>Outcome and Management</h3><p>While chronic therapy with nintedanib can be associated with transient mild-to-moderate serum aminotransferase elevations, it can also result in clinically apparent liver injury. Current recommendations are for monitoring of serum aminotransferase, alkaline phosphatase and bilirubin levels monthly during the first 3 months and every 3 months thereafter as needed. Patients who develop aminotransferase elevations on therapy should be monitored more carefully and considered for dose reduction to 100 mg twice daily with close follow up. Nintedanib therapy should be discontinued if jaundice or symptoms of liver injury arise or if serum ALT or AST levels rise above 5 times the ULN.</p><p>Drug Class: Pulmonary Fibrosis Agents</p><p>Other Drugs in the Class: <a href="/books/n/livertox/Pirfenidone/?report=reader">Pirfenidone</a></p></div></div><div id="Nintedanib.PRODUCT_INFORMATION"><h2 id="_Nintedanib_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p>
|
|
<b>REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Nintedanib – OFEV®</p><p>
|
|
<b>DRUG CLASS</b>
|
|
</p><p>Pulmonary Fibrosis Agents</p><p>
|
|
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Nintedanib" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
|
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Nintedanib.CHEMICAL_FORMULA_AND_STRUCTUR"><h2 id="_Nintedanib_CHEMICAL_FORMULA_AND_STRUCTUR_">CHEMICAL FORMULA AND STRUCTURE</h2><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figNintedanibTc"><a href="/books/NBK548135/table/Nintedanib.Tc/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figNintedanibTc" rid-ob="figobNintedanibTc"><img class="small-thumb" src="/books/NBK548135/table/Nintedanib.Tc/?report=thumb" src-large="/books/NBK548135/table/Nintedanib.Tc/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Nintedanib.Tc"><a href="/books/NBK548135/table/Nintedanib.Tc/?report=objectonly" target="object" rid-ob="figobNintedanibTc">Table</a></h4></div></div></div><div id="Nintedanib.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Nintedanib_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 12 December 2023</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Nintedanib.REF.kaplowitz.2013">Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013.<div><i>(Multi-authored textbook of hepatotoxicity published in 2013; does not discuss nintedanib).</i></div></div></li><li><div class="bk_ref" id="Nintedanib.REF.rockey.2008.939">Rockey
|
|
DC. Current and future anti-fibrotic therapies for chronic liver disease.
|
|
Clin Liver Dis
|
|
2008; 12: 939-62.
|
|
[<a href="/pmc/articles/PMC2610449/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2610449</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18984475" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18984475</span></a>]<div><i>(Review of the pathogenesis and cellular pathways of fibrosis in patients with chronic liver disease and status of antifibrotic agents, none of which have been shown to be effective in treating or preventing hepatic fibrosis).</i></div></div></li><li><div class="bk_ref" id="Nintedanib.REF.richeldi.2011.1079">Richeldi
|
|
L, Costabel
|
|
U, Selman
|
|
M, Kim
|
|
DS, Hansell
|
|
DM, Nicholson
|
|
AG, Brown
|
|
KK, et al.
|
|
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
|
|
N Engl J Med
|
|
2011; 365: 1079-87.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/21992121" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21992121</span></a>]<div><i>(Among 1066 patients with idiopathic pulmonary fibrosis enrolled in two studies of nintedanib [150 mg twice daily] versus placebo, the decline in forced vital capacity was less with nintedanib, but adverse events were more frequent and ALT or AST elevations above 3 times ULN occurred in 4.9-5.2% vs <1% on placebo, although no patient developed clinically apparent liver injury with jaundice).</i></div></div></li><li><div class="bk_ref" id="Nintedanib.REF4">Two new drugs for idiopathic pulmonary fibrosis.
|
|
Med Lett Drugs Ther
|
|
2014; 56 (1457): 123-4.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/25461229" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25461229</span></a>]<div><i>(Concise review of the mechanism of action, efficacy and safety of pirfenidone and nintedanib for idiopathic pulmonary fibrosis mentions that both agents can increase hepatic enzyme levels and dose adjustment may be required).</i></div></div></li><li><div class="bk_ref" id="Nintedanib.REF.richeldi.2014.2071">Richeldi
|
|
L, du Bois
|
|
RM, Raghu
|
|
G, Azuma
|
|
A, Brown
|
|
KK, Costabel
|
|
U, Cottin
|
|
V, et al.; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
|
|
N Engl J Med
|
|
2014; 370: 2071-82.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/24836310" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24836310</span></a>]<div><i>(Among 432 patients with idiopathic pulmonary fibrosis treated with 1 of 4 doses of nintedanib or placebo for 1 year, decline in vital capacity and number of pulmonary exacerbations were less in the 86 patients who received the highest dose [150 mg twice daily], but dermatologic and gastrointestinal side effects were more frequent, as were ALT or AST elevations above 3 times ULN [6 patients, 7.1%, vs none with placebo], but no clinically apparent liver injury was reported).</i></div></div></li><li><div class="bk_ref" id="Nintedanib.REF.chalasani.2015.1340">Chalasani
|
|
N, Bonkovsky
|
|
HL, Fontana
|
|
R, Lee
|
|
W, Stolz
|
|
A, Talwalkar
|
|
J, Reddy
|
|
KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study.
|
|
Gastroenterology
|
|
2015; 148: 1340-1352.e7.
|
|
[<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25754159" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, none were attributed to agents for pulmonary fibrosis).</i></div></div></li><li><div class="bk_ref" id="Nintedanib.REF.keating.2015.1131">Keating
|
|
GM. Nintedanib: a review of its use in patients with idiopathic pulmonary fibrosis.
|
|
Drugs
|
|
2015; 75: 1131-40.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/26063212" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26063212</span></a>]<div><i>(Review of the mechanism of action, pharmacology, efficacy and safety of nintedanib as therapy of idiopathic pulmonary fibrosis states that serum enzyme elevations during therapy "were reversible and were not associated with clinical manifestations of liver injury").</i></div></div></li><li><div class="bk_ref" id="Nintedanib.REF.abdelrahman.2016.2163">Abdel-Rahman
|
|
O, Bahie Eldin
|
|
N, ElHalawani
|
|
H.
|
|
Risk of selected gastrointestinal and hepatic toxicities in cancer patients treated with nintedanib: a meta-analysis.
|
|
Future Oncol
|
|
2016; 12: 2163-72.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/27301454" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27301454</span></a>]<div><i>(Meta-analysis of nine controlled trials of nintedanib in various forms of cancer found, rates of ALT elevations above 5 times ULN in 9.2% of 2029 nintedanib treated vs 2.7% of 1543 controls).</i></div></div></li><li><div class="bk_ref" id="Nintedanib.REF.kim.2017.1958">Kim
|
|
Y, Lee
|
|
SJ, Lee
|
|
JY, Lee
|
|
SH, Sun
|
|
JM, Park
|
|
K, An
|
|
HJ, et al.
|
|
Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
|
|
Cancer
|
|
2017; 123: 1958-64.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/28102887" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28102887</span></a>]<div><i>(Among 20 subjects with metastatic salivary gland cancer treated with nintedanib [200 mg twice daily], there were no objective responses, and adverse events including ALT elevations in 30% which were above 5 times ULN in 10%; no mention of clinically apparent liver injury).</i></div></div></li><li><div class="bk_ref" id="Nintedanib.REF.olin.2017.e107">Olin
|
|
JL, Woods
|
|
JA, Garner
|
|
SJ. Delayed presentation of hepatocellular liver injury after nintedanib administration.
|
|
Am J Ther
|
|
2017; 24: e107-e108.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/27574930" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27574930</span></a>]<div><i>(86 year old man developed fatigue 8 months after starting nintedanib [bilirubin normal, ALT ~410 U/L, Alk P normal], ALT levels having been normal before and for the first 7 months of treatment and returning to near normal rapidly after stopping).</i></div></div></li><li><div class="bk_ref" id="Nintedanib.REF.ikeda.2017.51">Ikeda
|
|
S, Sekine
|
|
A, Baba
|
|
T, Yamakawa
|
|
H, Morita
|
|
M, Kitamura
|
|
H, Ogura
|
|
T. Hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis: A single-center experience.
|
|
Respir Investig
|
|
2017; 55: 51-4.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/28012494" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28012494</span></a>]<div><i>(Among 32 patients with idiopathic pulmonary fibrosis treated with nintedanib at a single Japanese referral center, 59% developed ALT elevations which were above 3 times ULN in 6%, arising usually during the first week and resolving with dose interruption or reduction; no patient developed clinically apparent liver injury or jaundice).</i></div></div></li><li><div class="bk_ref" id="Nintedanib.REF.marzin.2018.357">Marzin
|
|
K, Kretschmar
|
|
G, Luedtke
|
|
D, Kraemer
|
|
S, Kuelzer
|
|
R, Schlenker-Herceg
|
|
R, Schmid
|
|
U, et al.
|
|
Pharmacokinetics of nintedanib in subjects with hepatic impairment. J Clin Pharmacol.
|
|
2018;58(3):357-363.
|
|
[<a href="/pmc/articles/PMC5836871/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5836871</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29106740" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29106740</span></a>]<div><i>(Single dose pharmacokinetic studies of nintedanib [100 mg] demonstrated an increase in exposure in patients with Child's A [2-fold] and B [8-fold] cirrhosis compared to healthy controls).</i></div></div></li><li><div class="bk_ref" id="Nintedanib.REF.ikeda.2017.10811">Ikeda
|
|
S, Sekine
|
|
A, Baba
|
|
T, Yamanaka
|
|
Y, Sadoyama
|
|
S, Yamakawa
|
|
H, Oda
|
|
T, et al.
|
|
Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis.
|
|
Sci Rep.
|
|
2017;7:10811.
|
|
[<a href="/pmc/articles/PMC5589740/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5589740</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28883482" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28883482</span></a>]<div><i>(Among 68 patients with idiopathic pulmonary fibrosis treated with nintedanib [150 mg twice daily] at a single Japanese referral center over a 1 year period, 46 [68%] developed ALT or AST elevations, which were above 3 times ULN in 16 [24%] and above 5 times ULN in 6 [9%], resolving in all patients upon stopping, and recurring in only 4 of 10 who restarted treatment at a lower dose; no mention of bilirubin elevations but 3 patients had mild epigastric pain; patients who developed enzyme elevations had a lower body surface area than those who did not, but similar body mass index).</i></div></div></li><li><div class="bk_ref" id="Nintedanib.REF.bendstrup.2019.173">Bendstrup
|
|
E, Wuyts
|
|
W, Alfaro
|
|
T, Chaudhuri
|
|
N, Cornelissen
|
|
R, Kreuter
|
|
M, Melgaard Nielsen
|
|
K, et al.
|
|
Nintedanib in idiopathic pulmonary fibrosis: practical management recommendations for potential adverse events.
|
|
Respiration
|
|
2019;97:173-184.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/30544129" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30544129</span></a>]<div><i>(Review of the adverse events associated with nintedanib therapy and expert recommendations on their detection, diagnosis and management, mentions that 8-16% of treated patients develop liver test abnormalities with values above 3 times ULN in 5%, usually arising within the first 3 months of treatment and resolving spontaneously or which dose adjustments [~80%]; the authors recommend monitoring before and monthly during the first 6 months of treatment and every 3 months thereafter).</i></div></div></li><li><div class="bk_ref" id="Nintedanib.REF.lancaster.2019.e000397">Lancaster
|
|
L, Crestani
|
|
B, Hernandez
|
|
P, Inoue
|
|
Y, Wachtlin
|
|
D, Loaiza
|
|
L, Quaresma
|
|
M, et al.
|
|
Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials.
|
|
BMJ Open Respir Res.
|
|
2019;6:e000397.
|
|
[<a href="/pmc/articles/PMC6530503/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6530503</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31179001" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31179001</span></a>]<div><i>(Among 1126 patients with idiopathic pulmonary fibrosis treated with nintedanib [150 mg twice daily] for a mean of 28 months vs 565 treated with placebo for 11 months in controlled trials, adverse events included hepatic enzyme elevations at event rates of 12.1 vs 3.4 per 100 patient-years; no mention of clinically apparent liver injury).</i></div></div></li><li><div class="bk_ref" id="Nintedanib.REF.distler.2019.2518">Distler
|
|
O, Highland
|
|
KB, Gahlemann
|
|
M, Azuma
|
|
A, Fischer
|
|
A, Mayes
|
|
MD, Raghu
|
|
G, et al.; SENSCIS Trial Investigators. Nintedanib for systemic sclerosis-associated interstitial lung disease.
|
|
N Engl J Med.
|
|
2019;380:2518-2528.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/31112379" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31112379</span></a>]<div><i>(Among 576 patients with idiopathic lung disease associated with systemic sclerosis treated with nintedanib [150 mg twice daily], the annual rate of change of forced vital capacity was -52 vs -93 mL, while total adverse events rates were similar [98% vs 96%], and while severe adverse events were more frequent with nintedanib [18% vs 12.5%] as were ALT or AST elevations of ≥3 times ULN [5% vs 0.7%], but none were associated with jaundice).</i></div></div></li><li><div class="bk_ref" id="Nintedanib.REF.flaherty.2019.1718">Flaherty
|
|
KR, Wells
|
|
AU, Cottin
|
|
V, Devaraj
|
|
A, Walsh
|
|
SLF, Inoue
|
|
Y, Richeldi
|
|
L, et al.; INBUILD Trial Investigators. Nintedanib in progressive fibrosing interstitial lung diseases.
|
|
N Engl J Med.
|
|
2019;381:1718-1727.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/31566307" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31566307</span></a>]<div><i>(Among 663 patients with progressive fibrosing interstitial lung disease treated with nintedanib vs placebo, decline in pulmonary function was less with nintedanib [forced vital capacity -81 mL vs -188 mL per year], and overall rates of total adverse events [96% vs 89%] and severe adverse events [18% vs 22%] were similar in both groups, although total discontinuations for side effects were greater with nintedanib [20% vs 10%] as were ALT elevations ≥3 times ULN [13% vs 2%], while ALT elevations accompanied by jaundice occurred in 1 patient in both groups).</i></div></div></li><li><div class="bk_ref" id="Nintedanib.REF.lasky.2020.4209">Lasky
|
|
JA, Criner
|
|
GJ, Lazarus
|
|
HM, Kohlbrenner
|
|
V, Bender
|
|
S, Richeldi
|
|
L. Safety of nintedanib in patients with idiopathic pulmonary fibrosis: global pharmacovigilance data.
|
|
Adv Ther.
|
|
2020;37:4209-4219.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/32767182" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32767182</span></a>]<div><i>(Analysis of a global pharmacovigilance database held by Boehringer Ingelheim had data on adverse events based upon 60,107 patient-years of treatment with nintedanib showed rates of hepatic enzyme elevations of 3.1 per 100 patient-years [/100 p-y], diarrhea in 30.2/100 p-y, bleeding in 3.7/100 p-y, and major cardiovascular events in 1.4/100 p-y).</i></div></div></li><li><div class="bk_ref" id="Nintedanib.REF.schmid.2021.244">Schmid
|
|
U, Weber
|
|
B, Sarr
|
|
C, Freiwald
|
|
M. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
|
|
BMC Pulm Med.
|
|
2021;21:244.
|
|
[<a href="/pmc/articles/PMC8293560/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8293560</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34289823" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34289823</span></a>]<div><i>(Measurement of plasma levels of nintedanib in treated patients demonstrated a positive relationship between plasma levels and occurrence of diarrhea and aminotransferase elevations as well as higher levels in women than men).</i></div></div></li><li><div class="bk_ref" id="Nintedanib.REF.librero_jim_nez.2022.244">Librero Jiménez
|
|
M, Heredia Carrasco
|
|
C, Fernández Cano
|
|
MDC. Severe hepatotoxicity secondary to nintedanib.
|
|
Rev Esp Enferm Dig.
|
|
2022;114:244-245.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/33371696" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33371696</span></a>]<div><i>(88 year old man with idiopathic pulmonary fibrosis developed weakness, pruritus and jaundice 2 years after starting nintedanib [bilirubin 3.7 mg/dL , ALT 32 U/L, Alk P 726 U/L, INR 1.3], with improvement but not complete resolution one month after stopping but no further follow up).</i></div></div></li><li><div class="bk_ref" id="Nintedanib.REF.jena.2022.1210">Jena
|
|
A, Aggarwal
|
|
T, Mitra
|
|
S, Singh
|
|
AK. Nintedanib-induced liver injury: not every liver injury is virus or vaccine-induced in the era of COVID-19.
|
|
Liver Int.
|
|
2022;42:1210-1211.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/35195327" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35195327</span></a>]<div><i>(70 year old man developed jaundice a week after a first dose of COVID-19 vaccine [BBV152: Covaxin] and 4.5 months after starting nintedanib for pulmonary fibrosis after COVID-19 infection [bilirubin 16.1 mg/dL, ALT 61 U/L, Alk P 181 U/L, INR 1.2], which resolved within 3 months of stopping nintedanib).</i></div></div></li><li><div class="bk_ref" id="Nintedanib.REF.raschi.2022.645">Raschi
|
|
E, Fusaroli
|
|
M, Gatti
|
|
M, Caraceni
|
|
P, Poluzzi
|
|
E, De Ponti
|
|
F. Liver injury with nintedanib: a pharmacovigilance-pharmacokinetic appraisal.
|
|
Pharmaceuticals (Basel). 2022;15:645.
|
|
[<a href="/pmc/articles/PMC9146184/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9146184</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35631471" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35631471</span></a>]<div><i>(Analysis of spontaneous adverse event reports related to nintedanib made to the FDA’s Adverse Event Reporting System identified 13,249 reports including 91 [0.7%] cases of liver injury 44% from Asia, most frequently in men, median age 68 years, leading to death in 26% and two positive rechallenges, the time to onset averaged 13.5 days).</i></div></div></li><li><div class="bk_ref" id="Nintedanib.REF.bare_i_.2023.2897">Barešić
|
|
M, Novak
|
|
S, Perković
|
|
D, Karanović
|
|
B, Mirić
|
|
F, Radić
|
|
M, Anić
|
|
B. Real world experience with nintedanib in connective tissue disease-related interstitial lung disease: a retrospective cohort study.
|
|
Clin Rheumatol.
|
|
2023;42:2897-2903.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/37393200" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37393200</span></a>]<div><i>(Among 25 patients with chronic fibrosing lung disease treated with nintedanib in three referral centers in Croatia, adverse events were reported by 16 [64%], diarrhea in 15 [60%], and abnormal liver tests in 1 [4%]).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK548135_pubdet_">Publication Details</h2><h3>Publication History</h3><p class="small">Last Update: <span itemprop="dateModified">December 12, 2023</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Nintedanib. [Updated 2023 Dec 12].<span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/livertox/Nimodipine/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/livertox/Niraparib/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobNintedanibTc"><div id="Nintedanib.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548135/table/Nintedanib.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Nintedanib.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_Nintedanib.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Nintedanib.Tc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NO.</th><th id="hd_h_Nintedanib.Tc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Nintedanib.Tc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Nintedanib.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Nintedanib</td><td headers="hd_h_Nintedanib.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/135267499" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">656247-17-5</a>
|
|
</td><td headers="hd_h_Nintedanib.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C31-H33-N5-O4</td><td headers="hd_h_Nintedanib.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SID: 135267499</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal106 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|